Companies › CellARTs
4 active drug programs in 4 registered trials: 4 Phase 1; Genitourinary; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Cell Maturation | – | Phase 1 | Infertility, Male | Dec 2026 |
| Genetic Reprogramming | – | Phase 1 | Infertility, Male | Dec 2026 |
| Genetic Screening | – | Phase 1 | Infertility, Male | Dec 2026 |
| Stem cell | – | Phase 1 | Infertility, Male | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06841861 | Stem cell | Phase 1 | Infertility, Male | Genitourinary | Dec 2026 |
| NCT06841861 | Genetic Screening | Phase 1 | Infertility, Male | Genitourinary | Dec 2026 |
| NCT06841861 | Genetic Reprogramming | Phase 1 | Infertility, Male | Genitourinary | Dec 2026 |
| NCT06841861 | Cell Maturation | Phase 1 | Infertility, Male | Genitourinary | Dec 2026 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.